BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28062671)

  • 1. Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes.
    Höpken UE
    Cancer Discov; 2017 Jan; 7(1):14-16. PubMed ID: 28062671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
    Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
    Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
    Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
    Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
    Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
    Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
    Mondello P; Tadros S; Teater M; Fontan L; Chang AY; Jain N; Yang H; Singh S; Ying HY; Chu CS; Ma MCJ; Toska E; Alig S; Durant M; de Stanchina E; Ghosh S; Mottok A; Nastoupil L; Neelapu SS; Weigert O; Inghirami G; Baselga J; Younes A; Yee C; Dogan A; Scheinberg DA; Roeder RG; Melnick AM; Green MR
    Cancer Discov; 2020 Mar; 10(3):440-459. PubMed ID: 31915197
    [No Abstract]   [Full Text] [Related]  

  • 6. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity.
    Lossos IS; Levy R; Alizadeh AA
    Leukemia; 2004 Nov; 18(11):1775-9. PubMed ID: 15385936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
    Saito M; Gao J; Basso K; Kitagawa Y; Smith PM; Bhagat G; Pernis A; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2007 Sep; 12(3):280-92. PubMed ID: 17785208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.
    Jaye DL; Iqbal J; Fujita N; Geigerman CM; Li S; Karanam S; Fu K; Weisenburger DD; Chan WC; Moreno CS; Wade PA
    J Pathol; 2007 Sep; 213(1):106-15. PubMed ID: 17573669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.
    Lossos IS
    Cancer Cell; 2007 Sep; 12(3):189-91. PubMed ID: 17785200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the Origin of Human Germinal Center B Cell-Derived Malignancies.
    Seifert M; Küppers R
    Methods Mol Biol; 2017; 1623():253-279. PubMed ID: 28589362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.
    Hatzi K; Jiang Y; Huang C; Garrett-Bakelman F; Gearhart MD; Giannopoulou EG; Zumbo P; Kirouac K; Bhaskara S; Polo JM; Kormaksson M; MacKerell AD; Xue F; Mason CE; Hiebert SW; Prive GG; Cerchietti L; Bardwell VJ; Elemento O; Melnick A
    Cell Rep; 2013 Aug; 4(3):578-88. PubMed ID: 23911289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
    Basso K; Dalla-Favera R
    Adv Immunol; 2010; 105():193-210. PubMed ID: 20510734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
    Jardin F; Ruminy P; Bastard C; Tilly H
    Pathol Biol (Paris); 2007 Feb; 55(1):73-83. PubMed ID: 16815642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
    Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
    Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of BCL6 during germinal center B cell development.
    Huang C; Melnick A
    Sci China Life Sci; 2015 Dec; 58(12):1226-32. PubMed ID: 26566802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
    Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
    Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
    [No Abstract]   [Full Text] [Related]  

  • 19. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.
    Venturutti L; Teater M; Zhai A; Chadburn A; Babiker L; Kim D; Béguelin W; Lee TC; Kim Y; Chin CR; Yewdell WT; Raught B; Phillip JM; Jiang Y; Staudt LM; Green MR; Chaudhuri J; Elemento O; Farinha P; Weng AP; Nissen MD; Steidl C; Morin RD; Scott DW; Privé GG; Melnick AM
    Cell; 2020 Jul; 182(2):297-316.e27. PubMed ID: 32619424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.